REUN

Reunion Neuroscience Inc. (REUN) | Rumor.io

Reunion Neuroscience

REUN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about REUN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 2

Reunion Neuroscience Inc. (REUN) stock halted last week and had another halt on May 6, which was a Saturday, sparking concerns about data accuracy.
A trader took a $59.74 loss in REUN due to emotional decision-making and is relearning discipline to avoid similar mistakes.
Analysts have a 80% buy consensus for REUN, indicating mild confidence in the stock, and it ran +22.0% on low volume after being mentioned by a trading system.

Generated by AI

Sentiment

Of the messages about REUN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Jun 1

Reunion Neuroscience Inc. ($REUN) has a strong scanner stock profile this morning, indicating potential for further growth.
The company has $13 million in the bank, positioning it for significant movement in the market.
$REUN has entered into a lucrative agreement with MPM BioImpact, valued at $13.1 million, resulting in a 71.01% price increase.

Generated by AI

Topics

Of the messages about REUN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Jun 1

Reunion Neuroscience Inc. (REUN) has announced a US$13.1 million take-private transaction with MPM BioImpact, with shareholders set to receive $1.12 per share in cash.
The acquisition is valued at approximately US$13.1 million, with Reunion Neuroscience entering into an agreement with MPM BioImpact for an all-cash transaction.
The deal would see Reunion Neuroscience acquired by MPM BioImpact, with the transaction expected to provide a significant return for shareholders, with REUN stock already experiencing a significant price increase.

Generated by AI

Community

Of the messages about REUN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	95.45%	95.45%	95.45%	73.58%
Newcomers	4.55%	4.55%	4.55%	26.42%

May 3

Reunion Neuroscience's clinic business will be listed on the TSX Venture Exchange, while the company's drug development business will remain on the Nasdaq and Toronto Stock Exchange.
The company's split aims to gain access to the first legal psilocybin market in the US, a move that could be seen as a strategic step for the business.
Reunion Neuroscience's business will be renamed to reflect its new focus, as part of the company's efforts to rebrand and expand its operations.

Generated by AI

Also Discussed

Investors talking about REUN also mention

#	Name	Attention
1	ATA Inc-ChinaATAI	0%new
2	Compass Pathways plc - ADRCMPS	0.06%+0.05
3	Definium Therapeutics, Inc.MNMD	0%+0
4	GH Research PLCGHRS	0%0
5	PIMCO Corporate & Income Strategy FundPCN	0%0
6	BNOX - Bionomics Limited	——
7	Enveric Biosciences Inc.ENVB	0%0
8	Alto Neuroscience Inc.ANRO	0%new
9	GBNH - Greenbrook TMS Inc.	——
10	Cybin Inc.CYBN	0.01%+0